Teva Said to Mull Sale of $2 Billion Active Ingredients Unit (1)

Teva Pharmaceutical Industries Ltd. is weighing options for its active ingredients business, including a possible sale, people with knowledge of the matter said, as takeovers of health-care assets continue to defy the global dealmaking slump.

The Israeli company is working with advisers as it seeks to gauge interest in the Teva API unit from potential buyers, according to the people. A deal could value the business at about $2 billion, they said.

Teva’s active pharmaceutical ingredients business comprises more than 400 APIs used in drugs to treat everything from migraines to diabetes. The business employs over 5,000 staff, according to ...